InflaRx N.V. (IFRX)

InflaRx N.V. (IFRX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $223M; returns 1 day +2.0%, 1 week +18.2%.

InflaRx N.V. is a clinical-stage biopharmaceutical company headquartered in Jena, Germany, focused on developing anti-inflammatory therapeutics by targeting the complement system, specifically C5a and C5aR inhibitors. The company's business model is primarily driven by its drug development pipeline, as current product sales are minimal.

Groups IFRX belongs to

• Biotechnology
• Biopharmaceutical
• Clinical Stage Biopharma
• Healthcare
• Pharmaceuticals
• Life Sciences
• Strategic Pivot
• R&D
• Autoimmune Diseases
• Dermatology
• Chronic Inflammatory Diseases

IFRX financial model: income statement, cash flow and balance sheet